Drug Information

Drug General Information
Drug ID
D0B1EQ
Former ID
DIB007516
Drug Name
Taspoglutide
Synonyms
BIM-51077; BIM-51079; BIM-51182; Glucagon agonists, Ipsen; ITM-077; R-1583; RG-1583; RO-5073031; Glucagon agonists, Beaufour-Ipsen
Indication Type 1 diabetes [ICD9: 250; ICD10:E10] Phase 3 [522861]
Company
Ipsen
Structure
Download
2D MOL
Formula
C152H232N40O45
CAS Number
CAS 275371-94-3
PubChem Compound ID
56842233
Target and Pathway
Target(s) Glucagon-like peptide 1 receptor Target Info Agonist [530530]
KEGG Pathway cAMP signaling pathway
Neuroactive ligand-receptor interaction
Insulin secretion
Reactome Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
G alpha (s) signalling events
Glucagon-type ligand receptors
WikiPathways GPCRs, Class B Secretin-like
Integration of energy metabolism
GPCR ligand binding
GPCR downstream signaling
References
Ref 522861ClinicalTrials.gov (NCT01018173) A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease. U.S. National Institutes of Health.
Ref 530530Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes. Diabet Med. 2009 Nov;26(11):1156-64.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.